Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KRRO - Korro Bio Inc.


IEX Last Trade
47.55
-2.410   -5.068%

Share volume: 99,870
Last Updated: Fri 30 Aug 2024 09:59:49 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$49.96
-2.41
-4.82%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
5.83%
1 Month
5.55%
3 Months
-5.03%
6 Months
1.64%
1 Year
9,904.19%
2 Year
2,194.23%
Key data
Stock price
$47.55
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.18 - $97.91
52 WEEK CHANGE
$101.40
MARKET CAP 
443.739 M
YIELD 
N/A
SHARES OUTSTANDING 
9.299 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
5.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$71,342
AVERAGE 30 VOLUME 
$72,059
Company detail
CEO:
Region: US
Website: frequencytx.com
Employees: 66
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Recent news